Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) Receives Average Recommendation of “Moderate Buy” from Brokerages

Shares of Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) have earned a consensus rating of “Moderate Buy” from the eighteen research firms that are covering the stock, Marketbeat Ratings reports. Two investment analysts have rated the stock with a sell rating, one has given a hold rating, twelve have assigned a buy rating and three have issued a strong buy rating on the company. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $110.9091.

Several brokerages have recently weighed in on GPCR. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Structure Therapeutics in a report on Friday, July 17th. Canaccord Genuity Group set a $111.00 price target on shares of Structure Therapeutics in a report on Friday, August 7th. HC Wainwright reduced their price objective on shares of Structure Therapeutics from $100.00 to $70.00 and set a “buy” rating for the company in a research report on Thursday, June 11th. Wall Street Zen upgraded Structure Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Monday, August 17th. Finally, Citigroup reiterated a “market outperform” rating on shares of Structure Therapeutics in a research report on Friday, August 7th.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Seven Fleet Capital Management LP grew its stake in shares of Structure Therapeutics by 197.8% during the 2nd quarter. Seven Fleet Capital Management LP now owns 26,800 shares of the company’s stock worth $1,442,000 after purchasing an additional 17,800 shares during the period. Wellington Management Group LLP lifted its stake in shares of Structure Therapeutics by 1.6% in the second quarter. Wellington Management Group LLP now owns 7,379,433 shares of the company’s stock valued at $396,054,000 after purchasing an additional 119,146 shares during the period. Handelsbanken Fonder AB purchased a new stake in Structure Therapeutics during the second quarter worth about $1,041,000. Avidity Partners Management LP purchased a new stake in Structure Therapeutics during the first quarter worth about $1,446,000. Finally, Bank of America Corp DE grew its position in Structure Therapeutics by 617.0% during the first quarter. Bank of America Corp DE now owns 227,132 shares of the company’s stock worth $10,948,000 after buying an additional 195,454 shares during the period. Institutional investors and hedge funds own 91.78% of the company’s stock.

Structure Therapeutics Price Performance

Shares of NASDAQ GPCR opened at $45.91 on Tuesday. The stock has a fifty day moving average price of $50.81 and a 200 day moving average price of $50.07. Structure Therapeutics has a 1-year low of $18.26 and a 1-year high of $94.90. The company has a market cap of $3.20 billion, a PE ratio of -45.91 and a beta of -1.43.

Structure Therapeutics (NASDAQ:GPCR) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($0.49) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.10). Analysts anticipate that Structure Therapeutics will post -1.84 earnings per share for the current fiscal year.

About Structure Therapeutics

Structure Therapeutics (NASDAQ:GPCR) is a clinical?stage biotechnology company focused on the discovery and development of oral small?molecule therapies that target G protein?coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.